Corbus Pharmaceuticals to Present Updated CRB-701 Data at ASCO 2026 — Corbus Pharmaceuticals Holdings, Inc.

Event summary

Corbus Pharmaceuticals will present updated Phase 1/2 clinical data for CRB-701 at ASCO 2026, focusing on head and neck squamous cell carcinoma (HNSCC) and cervical cancer.
Oral and poster presentations scheduled for May 29 and May 30, 2026, respectively.
CRB-701 is a next-generation Nectin-4-targeting antibody-drug conjugate (ADC) with FDA Fast Track designations in HNSCC and cervical cancer.
Corbus plans to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026.
Company anticipates reporting data on CRB-701 in combination with Keytruda in first-line HNSCC patients in Q4 2026.

The big picture

Corbus Pharmaceuticals is advancing its pipeline with CRB-701, a next-generation ADC targeting Nectin-4, which has shown promising early-stage results. The upcoming ASCO 2026 presentations will be critical in assessing the drug's potential in HNSCC and cervical cancer, areas with significant unmet medical needs. The strategic focus on combination therapies with established treatments like Keytruda could broaden CRB-701's market opportunities if clinical success is demonstrated.

What we're watching

Clinical Efficacy: How the updated durability and subgroup analysis data for CRB-701 will impact its competitive positioning in HNSCC and cervical cancer.
Regulatory Pathway: Whether the Fast Track designations will accelerate CRB-701's approval process and potential market entry.
Combination Therapy: The pace at which Corbus can advance CRB-701 in combination with Keytruda and the implications for first-line HNSCC treatment.